Exelixis, Inc. EXEL
69.84 USD -0.86 (-1.22%)
At closeNov 12, 2026, 4:00 PM EST
69.84 0.00 0.00%
After hours · Nov 12, 4:00 PM ET
69.67 Day range 70.95
39.71 52-week range 73.69
- YTD
- +59.34%
- 1 year
- +60.22%
News
marketbeat.com Exelixis Nears FDA Decision, Key Kidney Cancer Data for Zanzalintinib Exelixis NASDAQ: EXEL is preparing for a regulatory decision on its cancer drug candidate zanzalintinib and expects results from a kidney cancer study in the first quarter of next year, Chief…
seekingalpha.com Exelixis, Inc. (EXEL) Presents at Stifel 2026 Healthcare Conference 2026 Transcript Exelixis, Inc. (EXEL) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
marketbeat.com Exelixis Bets on Zanza as Next Cancer Franchise as FDA Decision Nears Exelixis NASDAQ: EXEL is working to build its next cancer drug franchise around zanzalintinib, or zanza, while continuing to grow its established CABO business, Chief Strategy Officer Andrew Peters…
seekingalpha.com Exelixis, Inc. (EXEL) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript Exelixis, Inc. (EXEL) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript
zacks.com Here's Why Exelixis (EXEL) is a Strong Growth Stock Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
fool.com The Top 5 Biotech Stocks I'd Buy Right Now Without Any Hesitation These are among the best the industry has to offer.
benzinga.com Leerink Partners Maintains Market Perform on Exelixis, Raises Price Target to $58 Leerink Partners analyst Asthika Goonewardene maintains Exelixis (NASDAQ:EXEL) with a Market Perform and raises the price target from $55 to $58.
benzinga.com Top 3 Health Care Stocks That May Fall Off A Cliff This Quarter Regeneron, AstraZeneca and Exelixis show overbought RSI readings after strong gains, warning momentum-focused investors of potential pullbacks.
benzinga.com HC Wainwright & Co. Maintains Buy on Exelixis, Raises Price Target to $78 HC Wainwright & Co. analyst Robert Burns maintains Exelixis (NASDAQ:EXEL) with a Buy and raises the price target from $56 to $78.
benzinga.com TD Cowen Maintains Buy on Exelixis, Raises Price Target to $76 TD Cowen analyst Yaron Werber maintains Exelixis (NASDAQ:EXEL) with a Buy and raises the price target from $55 to $76.
benzinga.com Morgan Stanley Maintains Equal-Weight on Exelixis, Raises Price Target to $60 Morgan Stanley analyst Sean Laaman maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and raises the price target from $53 to $60.
benzinga.com RBC Capital Maintains Sector Perform on Exelixis, Raises Price Target to $58 RBC Capital analyst Leonid Timashev maintains Exelixis (NASDAQ:EXEL) with a Sector Perform and raises the price target from $51 to $58.- benzinga.com Truist Securities Maintains Hold on Exelixis, Raises Price Target to $60 Truist Securities analyst Gregory Renza maintains Exelixis (NASDAQ:EXEL) with a Hold and raises the price target from $54 to $60.
benzinga.com Barclays Maintains Equal-Weight on Exelixis, Raises Price Target to $54 Barclays analyst Etzer Darout maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and raises the price target from $49 to $54.
benzinga.com AutoNation, Regeneron Pharmaceuticals, AstraZeneca And Other Big Stocks Moving Higher On Friday U.S. stocks fell Friday, but AutoNation jumped 8% after beating Q3 estimates; OneSpan, Grid Dynamics and others posted double-digit gains.
benzinga.com Exelixis Q3 2026 Earnings Call Transcript Exelixis (NASDAQ:EXEL) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide real-time…
benzinga.com Exelixis Affirms FY2026 Sales Guidance of $2.500B-$2.550B vs $2.549B Est Exelixis (NASDAQ:EXEL) affirms FY2026 sales outlook from $2.500 billion-$2.550 billion to $2.500 billion-$2.550 billion vs $2.549 billion estimate.- benzinga.com Exelixis Q3 Adj. EPS $0.94 Beats $0.80 Estimate, Sales $658.696M Beat $646.510M Estimate Exelixis (NASDAQ:EXEL) reported quarterly earnings of $0.94 per share which beat the analyst consensus estimate of $0.80 by 17.5 percent. This is a 20.51 percent increase over earnings of $0.78 per…
benzinga.com 9 Health Care Stocks Whale Activity In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…- benzinga.com Citizens Maintains Market Outperform on Exelixis, Raises Price Target to $65 Citizens analyst Silvan Turkcan maintains Exelixis (NASDAQ:EXEL) with a Market Outperform and raises the price target from $55 to $65.
benzinga.com RBC Capital Maintains Sector Perform on Exelixis, Raises Price Target to $51 RBC Capital analyst Leonid Timashev maintains Exelixis (NASDAQ:EXEL) with a Sector Perform and raises the price target from $45 to $51.- benzinga.com RBC Capital Maintains Sector Perform on Exelixis, Lowers Price Target to $45 RBC Capital analyst Leonid Timashev maintains Exelixis (NASDAQ:EXEL) with a Sector Perform and lowers the price target from $46 to $45.
benzinga.com Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In FDA extends Exelixis NDA review for zanzalintinib to March 2027. Analyst evaluates stock volatility and revenue outlook.- benzinga.com Exelixis Announces Three-Month FDA Review Period Extension For Its Zanzalintinib New Drug Application In Combination With Atezolizumab For The Treatment Of Metastatic Colorectal Cancer In response to an FDA information request, Exelixis had submitted updated safety and efficacy data, which the FDA has deemed a major amendment. The updated Prescription Drug User Fee Act action date…
- benzinga.com Exelixis Announces Appellate Court Affirms Key Part Of 2024 Judgement Of U.S. District Court In Favor Of Co. Against MSN Laboratories; Appellate Court Upholds District Court Decision That Three Patents Are Not Invalid Covering Crystalline Malate Salt Of Cabozantinib Exelixis, Inc. (NASDAQ:EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN Laboratories Private Limited et al. (MSN), Civil Action No. 22-00228 (Consolidated), the U.S. Court…
- benzinga.com BMO Capital Initiates Coverage On Exelixis with Market Perform Rating, Announces Price Target of $54 BMO Capital analyst David Lebowitz initiates coverage on Exelixis (NASDAQ:EXEL) with a Market Perform rating and announces Price Target of $54.
- benzinga.com Truist Securities Maintains Hold on Exelixis, Lowers Price Target to $52 Truist Securities analyst Gregory Renza maintains Exelixis (NASDAQ:EXEL) with a Hold and lowers the price target from $56 to $52.
- benzinga.com Stifel Maintains Hold on Exelixis, Raises Price Target to $51 Stifel analyst Stephen Willey maintains Exelixis (NASDAQ:EXEL) with a Hold and raises the price target from $47 to $51.
- benzinga.com Exelixis Lowers FY2026 Sales Guidance from $2.525B-$2.625B to $2.500B-$2.550B vs $2.595B Est Exelixis (NASDAQ:EXEL) lowers FY2026 sales outlook from $2.525 billion-$2.625 billion to $2.500 billion-$2.550 billion vs $2.595 billion estimate.
- benzinga.com Exelixis Q2 Adj. EPS $0.91 Beats $0.79 Estimate, Sales $628.700M Miss $635.951M Estimate Exelixis (NASDAQ:EXEL) reported quarterly earnings of $0.91 per share which beat the analyst consensus estimate of $0.79 by 15.19 percent. This is a 21.33 percent increase over earnings of $0.75 per…
- benzinga.com Morgan Stanley Maintains Equal-Weight on Exelixis, Raises Price Target to $53 Morgan Stanley analyst Sean Laaman maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and raises the price target from $50 to $53.
- benzinga.com Barclays Maintains Equal-Weight on Exelixis, Raises Price Target to $49 Barclays analyst Etzer Darout maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and raises the price target from $45 to $49.
- benzinga.com Wells Fargo Maintains Equal-Weight on Exelixis, Raises Price Target to $49 Wells Fargo analyst Eva Fortea Verdejo maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and raises the price target from $40 to $49.
- benzinga.com RBC Capital Maintains Sector Perform on Exelixis, Raises Price Target to $46 RBC Capital analyst Leonid Timashev maintains Exelixis (NASDAQ:EXEL) with a Sector Perform and raises the price target from $43 to $46.
benzinga.com Truist Securities Maintains Hold on Exelixis, Raises Price Target to $56 Truist Securities analyst Gregory Renza maintains Exelixis (NASDAQ:EXEL) with a Hold and raises the price target from $54 to $56.- benzinga.com UBS Maintains Neutral on Exelixis, Raises Price Target to $52 UBS analyst Ashwani Verma maintains Exelixis (NASDAQ:EXEL) with a Neutral and raises the price target from $43 to $52.
- benzinga.com HC Wainwright & Co. Reiterates Buy on Exelixis, Maintains $56 Price Target HC Wainwright & Co. analyst Robert Burns reiterates Exelixis (NASDAQ:EXEL) with a Buy and maintains $56 price target.
benzinga.com This PVH Analyst Turns Bearish; Here Are Top 3 Downgrades For Thursday Wall Street analysts change outlook on top names, with downgrades and initiations. See analyst ratings page for complete view.- benzinga.com Truist Securities Downgrades Exelixis to Hold, Raises Price Target to $54 Truist Securities analyst Gregory Renza downgrades Exelixis (NASDAQ:EXEL) from Buy to Hold and raises the price target from $51 to $54.
- benzinga.com Citizens Maintains Market Outperform on Exelixis, Raises Price Target to $55 Citizens analyst Silvan Turkcan maintains Exelixis (NASDAQ:EXEL) with a Market Outperform and raises the price target from $50 to $55.
benzinga.com Exelixis Provides 'A Highly Defensive Investment Profile:' Analyst Exelixis reported final STELLAR-303 data showing a survival trend for zanzalintinib combo in metastatic colorectal cancer patients.- benzinga.com Exelixis Reports Final STELLAR‑303 Analysis; Zanzalintinib In Combination With Tecentriq Showed Non‑Significant OS Trend Favoring Combo In Non‑Liver Metastases mCRC Exelixis, Inc. (NASDAQ:EXEL) today announced results from the final analysis of the dual primary endpoint of overall survival (OS) in the subset of patients without active liver metastases (non-liver…
- benzinga.com Exelixis Enters Clinical Development Collaboration With Merck For Its KEYTRUDA QLEX Injection In Combination With Zanzalintinib In The STELLAR-316 Phase 3 Trial STELLAR-316 is a planned phase 3 pivotal trial in patients with resected stage II/III colorectal cancer (CRC). Under the terms of the clinical development collaboration with Merck, Exelixis is…
benzinga.com Prologis To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday Top Wall Street analysts changed their outlook on top names. See all rating changes, including upgrades/downgrades, on analyst ratings page.- benzinga.com HC Wainwright & Co. Maintains Buy on Exelixis, Raises Price Target to $56 HC Wainwright & Co. analyst Robert Burns maintains Exelixis (NASDAQ:EXEL) with a Buy and raises the price target from $54 to $56.
- benzinga.com TD Cowen Maintains Buy on Exelixis, Raises Price Target to $55 TD Cowen analyst Yaron Werber maintains Exelixis (NASDAQ:EXEL) with a Buy and raises the price target from $51 to $55.
- benzinga.com Morgan Stanley Maintains Equal-Weight on Exelixis, Raises Price Target to $50 Morgan Stanley analyst Sean Laaman maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and raises the price target from $49 to $50.
benzinga.com Stifel Maintains Hold on Exelixis, Raises Price Target to $47 Stifel analyst Stephen Willey maintains Exelixis (NASDAQ:EXEL) with a Hold and raises the price target from $44 to $47.- benzinga.com Wells Fargo Maintains Equal-Weight on Exelixis, Raises Price Target to $40 Wells Fargo analyst Eva Fortea Verdejo maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and raises the price target from $35 to $40.
- benzinga.com Exelixis Initiates Stellar-201 Phase 2 Trial Of Zanzalintinib In Recurrent Meningioma; Board Authorizes $750M Stock Repurchase Program In May 2026 Dr. Morrissey continued: "Our R&D organization is on track to deliver multiple milestones this year across our zanzalintinib pivotal development program. We expect key data readouts from STELLAR-303…